2270 related articles for article (PubMed ID: 17996658)
1. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
2. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
3. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
[TBL] [Abstract][Full Text] [Related]
4. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Maclaine GD; Patel H
Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
[TBL] [Abstract][Full Text] [Related]
6. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
7. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
8. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
9. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
[TBL] [Abstract][Full Text] [Related]
10. Effective use of statins to prevent coronary heart disease.
Crouch MA
Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696
[TBL] [Abstract][Full Text] [Related]
11. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
12. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
13. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
14. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
Garmendia F; Brown AS; Reiber I; Adams PC
Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
[TBL] [Abstract][Full Text] [Related]
15. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Badia X; Russo P; Attanasio E
Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
[TBL] [Abstract][Full Text] [Related]
16. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
McPherson R; Angus C; Murray P; Genest J;
Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
[TBL] [Abstract][Full Text] [Related]
20. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Joukhadar C; Klein N; Prinz M; Schrolnberger C; Vukovich T; Wolzt M; Schmetterer L; Dorner GT
Thromb Haemost; 2001 Jan; 85(1):47-51. PubMed ID: 11204586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
